A phase II Study of Methotrexate, Lenalidomide and Rituximab Induction in Newly Diagnosed Primary CNS Lymphoma

Tata Memorial Center0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•Patients with histologically proven PCNSL
•Age > 18 years
•ECOG PS <4
•At least one bi-dimensionally measurable target lesion on MRI
•Adequate bone marrow function with absolute leukocytes > 2000/mm3, neutrophil count (ANC) > 1000/mm3, haemoglobin > 8 g/dl and platelets > 100 000/mm3
•Adequate liver function with Serum SGOT/AST or SGPT/ALT < 3.0 X Upper Limit of Normal ULN ; bilirubin < 1.5 X LNS
•Creatinine clearance more than 60 ml/min
•Men and women of child bearing age should agree to use reliable contraceptive
•Neuropathy of >= grade 2 severity

•HIV infection
•Prior history of organ transplantation or other cause of severe immunodeficiency
•History of heart disease and/or impaired cardiac function (ECG QTc >450msec, congenital long QT syndrome, history of ventricular tachyarrhythmia, ventricular fibrillation, congestive heart failure nyha iii/iv, uncontrolled hypertension)
•Pregnancy or breast feeding Hypersensitivity to lenalidomide
•Active hepatitis B and C
•Prior history of malignancies within 3 years

发起方

Tata Memorial Center